國立高雄大學圖資館 |

Language: English

Back

Lung cancernew understandings and th...

Chiang, Anne C.

Lung cancernew understandings and therapies /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Lung canceredited by Anne C. Chiang, Roy S. Herbst.
Reminder of title:	new understandings and therapies /
other author:	Chiang, Anne C.
Published:	Cham :Springer International Publishing :2021.
Description:	vi, 264 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	LungsCancer.
Online resource:	https://doi.org/10.1007/978-3-030-74028-3
ISBN:	9783030740283$q(electronic bk.)

Lung cancernew understandings and therapies /
Lung cancernew understandings and therapies /[electronic resource] :edited by Anne C. Chiang, Roy S. Herbst. - Cham :Springer International Publishing :2021. - vi, 264 p. :ill. (some col.), digital ;24 cm. - Current cancer research,2199-2592. - Current cancer research..

Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

ISBN: 9783030740283$q(electronic bk.)

Standard No.: 10.1007/978-3-030-74028-3doiSubjects--Topical Terms:

308833
Lungs
--Cancer.

LC Class. No.: RC280.L8

Dewey Class. No.: 616.99424

Lung cancernew understandings and therapies /
LDR:02328nmm a2200337 a 4500 001 609690
003 DE-He213
005 20210930163851.0
006 m d
007 cr nn 008maaau
008 220222s2021 sz s 0 eng d
020 $a 9783030740283$q(electronic bk.)
020 $a 9783030740276$q(paper)
024 7 $a 10.1007/978-3-030-74028-3 $2 doi
035 $a 978-3-030-74028-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99424 $2 23
090 $a RC280.L8 $b L963 2021
245 0 0 $a Lung cancer $h [electronic resource] : $b new understandings and therapies / $c edited by Anne C. Chiang, Roy S. Herbst.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2021.
300 $a vi, 264 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Current cancer research, $x 2199-2592
505 0 $a Tumor Microenvironment: Immune Effector and Suppressor Imbalance -- Biomarkers: is tumor mutational burden the new prognostic grail? -- Liquid biopsies: new technology and evidence -- Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance -- What can we learn from acquired resistance? -- Management of Brain Metastases -- Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors -- Therapeutic Advances in Small Cell Lung Cancer Management -- Small Cell Lung Cancer: Biology Advances -- Immunotherapy and Radiotherapy: New Strategies -- Ultimate Precision: Targeting Cancer but not Normal Self-Replication -- Index.
520 $a Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
650 0 $a Lungs $x Cancer. $3 308833
650 0 $a Lungs $x Cancer $x Treatment. $3 531376
650 1 4 $a Cancer Research. $3 273660
650 2 4 $a Molecular Medicine. $3 273932
650 2 4 $a Oncology. $3 195181
700 1 $a Chiang, Anne C. $3 907406
700 1 $a Herbst, Roy S. $3 907407
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Current cancer research. $3 558904
856 4 0 $u https://doi.org/10.1007/978-3-030-74028-3
950 $a Medicine (SpringerNature-11650)